As a leader in the bioprinting industry, CELLINK has decided to open an office in France where there is a flourishing scene in the biotech field. The company currently has offices in six cities worldwide; Boston, Gothenburg, Blacksburg, Kyoto, Stuttgart and Freiburg. Thanks to the newly opened office in Lyon, CELLINK will be able to offer a direct sales channel on the market through its own sales team.
”Opening an office in Lyon is part of our continuous effort to cover our global core markets with a direct presence; increasing our sales efforts, and improving our stellar application support. The new office will bring us closer to our customer, allowing us to serve them better with our wide portfolio and innovative applications.” – Torben Thölix, Head of Global Sales.
The French branch will offer the full product portfolio of CELLINK and its subsidiaries, Dispendix and cytena. Together with a strong sales force and applications support, the new office in France will strengthen CELLINK’s presence in central Europe and enable a closer dialogue with the local bioprinting community.
For more information, please contact: Erik Gatenholm, CEO Gusten Danielsson, CFO Phone: EU +46 73 267 00 00 Phone: +46 70 991 86 04 US +1 (650) 515 5566 US +1 (857) 332 2138 Email: [email protected] Email: [email protected] About CELLINK CELLINK is the leading 3D bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK. Erik Penser Bank AB is the company’s certified adviser, available by phone at +46 846 383 00 and by email at: [email protected] .